The conversations on this week’s podcast are with Vibhor Gupta, director and founder of Pangaea Data, and endogene.bio CEO María Teresa Pérez Zaballos.
Times:
03:09 Pangaea Data
23:43 endogene.bio
Endogene.bio
endogene.bio is a precision medicine company based in France developing a non-invasive diagnostic for endometriosis. The company’s aim is to apply precision medicine to female health.
endogene.bio was formed in 2022 by Maria Teresa Perez Zaballos and Cristina Fernandez Molina. Its innovations include a non-invasive diagnostic approach that uses menstrual blood rather than traditional blood draws or invasive surgery. By focusing on the uterine environment directly, the company aims to replace the current “gold standard” of laparoscopic surgery with a high-signal “liquid biopsy” that can be collected at home.
The company recently published a preprint, “Beyond one-size-fits-all: single-cell transcriptomic signatures predict drug efficacy and reveal responder subgroups in endometriosis.”
The company’s most recent scientific output, it was published in January 2026, and shows how the company uses single-cell transcriptomic signatures to map the molecular heterogeneity of the disease. The research has identified distinct “responder subgroups,” suggesting that endometriosis is not a single condition but a collection of cellular programmes that dictate how a patient will react to specific therapies. This primary data positions endogene.bio’s platform as both a diagnostic tool and a predictive framework for patient stratification in clinical trials, aiming to move the field toward personalized treatment selection.
Pangaea Data
Pangaea Data provides a clinical-grade AI platform, PALLUX, designed to identify untreated, misdiagnosed, and under-treated patients by extracting intelligence from unstructured records.
The platform emulates clinical reasoning to scan doctors’ notes and pathology reports, identifying care gaps across conditions such as oncology, rare diseases, and chronic kidney disease. It operates behind the healthcare organisation’s firewall to ensure data privacy while integrating directly into existing EHR workflows and ambient listening tools.
The platform’s “Privacy by Design” architecture allows it to scale across multiple disease areas without the need for manual data labelling. By mapping clinical features and disease trajectories, PALLUX provides clinicians with a single dashboard to access actionable insights. The methodology is currently deployed across 13 countries, helping pharmaceutical companies and healthcare providers discover up to five times more patients who would otherwise be missed by conventional search methods.
In December 2025, the London-headquartered company announced a multi-year strategic collaboration with AstraZeneca to advance precision healthcare through multimodal AI. The collaboration focuses on co-developing an enterprise-grade platform that fuses clinical, imaging, and genomic data to improve real-time treatment recommendations and speed up clinical trial recruitment.
To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com